The Queensland Drug Repurposing Initiative (QDRI) aims to fast-track new treatments for neurodegenerative diseases such as Parkinson’s disease.
Our research investigates whether drugs already approved to treat other diseases can also help treat neurodegeneration.
Phase II clinical trials will be conducted in major Queensland hospitals and research centres for drugs prioritised by an international expert panel after showing robust evidence of their potential to be effective.
Our team will create a large-scale clinical drug repurposing and biomarkers initiative in partnership with the UK Cure Parkinson’s Trust (CPT) and Linked Clinical Trials Initiative (LCT) with funding from the Advance Queensland program and Shake It Up Australia Foundation.
This initiative will establish Queensland as a hub for drug repurposing research while rapidly advancing cost-effective treatments for neurodegenerative diseases towards the clinic.
Please contact our clinical trials team if you are a person with Parkinson’s disease and are interested in participating in our clinical trials.
Contact
Clinical Trials Assistant
Sue Perry
susan.perry@uq.edu.au or qdri.research@uq.edu.au
Clinical Trials Manager
Helen Woodhouse
h.woodhouse@uq.edu.au or
qdri.research@uq.edu.au
07 3346 5043
Chief investigators
Research collaborators
- Dr Richard Gordon - QUT
- Professor George Mellick - Griffith University
- Dr Rob Adam - RBWH UQ Faculty of Medicine
- Professor Rod Minchin - UQ SBMS
- Associate Professor Trent Woodruff - UQ SBMS
QDRI staff
Our clinical trials will evaluate the efficacy of prioritised repurposed drugs as promising disease-modifying treatments for Parkinson’s disease. These drugs have been shortlisted by the Cure Parkinson’s Trust Linked Clinical Trials (LCT) program and have been rigorously evaluated for their potential to slow or halt the progression of the disease.
There are no clinical trials needing participation at the moment.
Our ancillary clinical research projects are focused on discovery and validation of clinical biomarkers for Parkinson’s disease and to evaluate the effectiveness of the drugs that are being tested in our clinical trials. There are currently no available biomarkers to conclusively diagnose the onset of Parkinson’s disease or to track its progression in people diagnosed with the disease. Our research is using multidisciplinary approaches to discover and confirm novel markers of disease onset and progression.
Enrolment in clinical research projects
We are currently seeking people with Parkinson’s disease as well as healthy control participants for our biomarkers research program. If you are interested in participating in any of our ongoing clinical research projects please contact our clinical research team.
Clinical Trials Assistant
Sue Perry
Email: qdri.research@uq.edu.au
Clinical Trials Manager
Helen Woodhouse
Email: h.woodhouse@uq.edu.au or qdri.research@uq.edu.au
Tel: 07 3346 5043
Our partners
